BioSpace News Archive

Tiziana Life Sciences PLC announced positive clinical results for its second secondary progressive multiple sclerosis patient in a June 8th press release.

IRLAB Therapeutics IRLAB announced that additional expertise is added to the company’s management team to leverage opportunities arising from recent commercial and scientific successes.

REGENXBIO Inc. is celebrating the opening of its new Manufacturing Innovation Center gene therapy manufacturing facility.

Revolution Medicines, Inc., a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, announced that the company will participate in the 43rd Annual Goldman Sachs Global Healthcare Conference.

Resolution Medical, a portfolio company of Arcline Investment Management and a premier vertically integrated medical device contract development and manufacturing organization, announced that it has acquired LifeTec Group™.

Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced Joydeep Goswami, Chief Strategy and Corporate Development Officer, will also serve as interim Chief Financial Officer while the company conducts a search for a permanent CFO.

VectivBio Holding AG published the invitation to the 2022 Annual General Meeting, which will be held on Thursday, June 30, 2022, at 2:00 p.m. CEST / 8:00 a.m. EDT at the offices of VectivBio Holding AG at Aeschenvorstadt 36, 4051 Basel, Switzerland.

Lipogems is pleased to announce the unconditional approval by the U.S. Food and Drug Administration (FDA) to conduct an Investigational Device Exemption (IDE) study for treatment of knee osteoarthritis (OA) compared to corticosteroids for a period of 12 months.

Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted sixteen new employees options to purchase a total of 35,050 shares of the Company’s common stock at an exercise price per share of $23.62, which was the closing price on June 8, 2022, and restricted stock units to acquire a total of 17,525 shares of the Company’s common stock.

Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, announced today that Sam Samad will become Executive Vice President and Chief Financial Officer.